Journal Article Research Support, Non-U.S. Gov't Ppublish 8 citations
PubMed: 35321627 DOI: 10.1080/21645515.2022.2040330
mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic.
Hum Vaccin Immunother 18(1):2040330
Authors: Peixian Chen, Xiaoye Shi, Weixin He, Guowei Zhong, Yan Tang, Hailin Wang, Peidong Zhang
Affiliations
- Zhujiang Hospital, Southern Medical University/The Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, People's Republic of China.
- Nanfang Hospital, Southern Medical University/The First School of Clinical Medicine, Southern Medical University, No, Guangzhou, Guangdong, People's Republic of China.
- School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong, People's Republic of China.
- Department of Cardiology, Heart Center, People's Hospital of Guangning County, Zhaoqing City, Guangdong, People's Republic of China.
- Department of Cardiology, Heart Center, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China.
Abstract
As an acute respiratory infectious disease, COVID-19 threatens the safety of global public health. Given the current lack of specific treatment against this disease, research and development of vaccines have become sharp weapons for overcoming the pandemic. mRNA vaccines have become the lead in COVID-19 vaccination strategies due to their advantages, such as rapid industrial production and efficacy. A total of 137 COVID-19 vaccines have entered the clinical trial stage, among which 23 are mRNA vaccines, accounting for 17% of the total vaccines. Herein, we summarize the research and developmental processes of mRNA vaccines as well as the approach for protecting the human body against infection. Focusing on the latest clinical trial data of two COVID-19 mRNA vaccines from Pfizer and Modena, we discuss their effectiveness and safety. Finally, we analyze the challenges and problems that mRNA vaccines face in controlling the COVID-19 pandemic.
MeSH
Safety, Vaccines, Rna, Messenger, Covid-19, Immunity, Research, Pandemics, Therapeutics, Communicable Diseases
Cited by
- Decoding trends in mRNA vaccine research: A comprehensive bibliometric study. Hum Vaccin Immunother, 2024
- COVID-19 vaccinated children, adolescents, and young adults with acute lymphoblastic leukemia show spike reactive antibodies and multifunctional T-cells. Int J Cancer, 2024
- Deciphering the Immunogenicity of Monkeypox Proteins for Designing the Potential mRNA Vaccine. ACS Omega, 2023
- Evolution of global scientific collaboration in mRNA vaccine research: Insights from bibliometric and social network analysis (2010~2023). Hum Vaccin Immunother, 2023
- Durability of humoral and cell-mediated immune response after SARS-CoV-2 mRNA vaccine administration. J Med Virol, 2023
- Comparison of SARS-CoV-2 immune responses following vaccination with Comirnaty (Pfizer) and Vaxzevria (AstraZeneca) in healthy individuals with or without prior SARS-CoV-2 infection. Front Immunol, 2025
- The Main Protease of SARS-CoV-2 as a Target for Phytochemicals against Coronavirus. Plants (Basel), 2022